DUBLIN, IRELAND | January 27, 2026 — ICON plc, a global clinical research organization, announced a significant expansion of oncology research capabilities within its Accellacare Site Network through a new partnership with the Brian Moran Cancer Institute (BMCI) at Duly Health and Care in Illinois. The opening of this flagship oncology site strengthens ICON’s ability to support oncology clinical trials, enhance investigator access, and address one of the most persistent challenges in cancer research: patient recruitment and site readiness for complex studies.
Science Significance
From a scientific standpoint, the expansion enhances the clinical research ecosystem supporting oncology drug development. The Brian Moran Cancer Institute brings together medical oncology, radiation oncology, and multiple surgical oncology subspecialties within a single, integrated care and research environment. This multidisciplinary structure is critical for modern oncology trials, which increasingly involve biomarker-driven protocols, combination regimens, and precision medicine approaches. By embedding clinical research capabilities within a high-volume oncology care setting, Accellacare enables faster study initiation, improved protocol feasibility, and higher-quality data generation, all of which are essential to advancing translational cancer science.
Regulatory Significance
The partnership has clear Good Clinical Practice (GCP) implications. Oncology trials are among the most highly scrutinized clinical programs due to patient vulnerability, complex endpoints, and intensive safety monitoring requirements. Expanding the Accellacare Site Network with a dedicated oncology institute strengthens regulatory compliance, investigator oversight, and data integrity across trials conducted at the site. For sponsors, access to a site network operated by an experienced global CRO like ICON provides confidence that regulatory expectations from the FDA, EMA, and other health authorities can be met consistently across regions. This integration supports smoother inspections, more robust documentation, and higher trial execution standards.
Business Significance
Advertisement
Strategically, the announcement reinforces ICON’s position as a leader in site-based clinical research solutions. Oncology represents one of the largest and fastest-growing segments of global clinical development spend, driven by an expanding pipeline of targeted therapies, immuno-oncology agents, and cell and gene therapies. By expanding Accellacare’s oncology footprint in the United States, ICON enhances its value proposition to pharmaceutical and biotechnology sponsors seeking reliable, scalable trial infrastructure. The partnership also strengthens ICON’s competitive differentiation by combining global CRO capabilities with localized, high-performing research sites, enabling sponsors to reduce timelines, control costs, and mitigate operational risk.
Patients’ Significance
For patients, the impact is direct and meaningful. The Brian Moran Cancer Institute provides access to innovative cancer treatments and clinical trials closer to where patients live, reducing the need for long-distance travel to academic centers. This is particularly important in oncology, where trial participation remains limited despite high patient interest. By expanding Accellacare’s oncology research capacity, ICON helps broaden patient access to investigational therapies, offering new options for individuals with limited standard-of-care alternatives. Improved access also supports more diverse and representative trial populations, which is increasingly recognized as essential for equitable drug development.
Policy Significance
At a policy level, the development aligns with broader healthcare and regulatory goals focused on improving clinical trial access, accelerating innovation, and strengthening research infrastructure. Regulators and policymakers continue to emphasize the importance of community-based trial sites to complement academic medical centers, particularly in oncology. Partnerships like this support national and international efforts to decentralize clinical research, enhance patient enrollment, and improve efficiency without compromising safety or data quality. The expansion also reflects policy momentum toward public–private collaboration in advancing cancer research.
ICON’s expansion of its Accellacare Site Network through the Brian Moran Cancer Institute partnership represents a strategic investment in the future of oncology clinical research. By strengthening site-based capabilities, enhancing regulatory rigor, and improving patient access, the initiative underscores how clinical infrastructure innovation plays a critical role in advancing regulated drug development. For the cGxP.wire audience, this announcement highlights the growing importance of high-quality, GCP-compliant site networks in delivering faster, more reliable oncology trials and ultimately bringing new cancer therapies to patients.
Source: ICON plc press release
